Literature DB >> 19424802

Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Lucette A Cysique1, Bruce J Brew.   

Abstract

This article presents a review of studies that have investigated the neuropsychological effects of antiretroviral treatment (ART) for HIV-1 infection. It provides a brief overview of the era of monotherapy, dual-therapy, and an extended overview of the current era of combination antiretroviral therapy (CART). This review highlights that while CART has had a dramatic effect on the incidence and the severity of HIV-associated neurocognitive disorders (HAND), HAND, in its mild form, still remains prevalent. New causes of this sustained prevalence are poor CNS penetration of some antiretroviral agents, drug resistance, poor adherence, potential neurotoxicity, co-morbidities such as the long-term CART side effects in relation to cardio-vascular disease, and chronic HIV brain infection that may facilitate the expression of new forms of neurodegenerative processes. The review emphasizes the need to address methodological limitations of published studies and the need for large and representative cross-disciplinary longitudinal investigations across the HIV illness span.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424802     DOI: 10.1007/s11065-009-9092-3

Source DB:  PubMed          Journal:  Neuropsychol Rev        ISSN: 1040-7308            Impact factor:   7.444


  85 in total

1.  Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals.

Authors:  M A Cole; J B Margolick; C Cox; X Li; O A Selnes; E M Martin; J T Becker; H A Aronow; B Cohen; N Sacktor; E N Miller
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

2.  Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir.

Authors:  G Pialoux; S Fournier; A Moulignier; J D Poveda; F Clavel; B Dupont
Journal:  AIDS       Date:  1997-08       Impact factor: 4.177

3.  Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

Authors:  M C Strain; S Letendre; S K Pillai; T Russell; C C Ignacio; H F Günthard; B Good; D M Smith; S M Wolinsky; M Furtado; J Marquie-Beck; J Durelle; I Grant; D D Richman; T Marcotte; J A McCutchan; R J Ellis; J K Wong
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

Authors:  Valerio Tozzi; Pietro Balestra; Rita Bellagamba; Angela Corpolongo; Maria Flora Salvatori; Ubaldo Visco-Comandini; Chrysoula Vlassi; Marinella Giulianelli; Simonetta Galgani; Andrea Antinori; Pasquale Narciso
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

5.  Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death.

Authors:  N C Sacktor; H Bacellar; D R Hoover; T E Nance-Sproson; O A Selnes; E N Miller; G J Dal Pan; C Kleeberger; A Brown; A Saah; J C McArthur
Journal:  J Neurovirol       Date:  1996-12       Impact factor: 2.643

6.  Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.

Authors:  N Sacktor; N Nakasujja; R Skolasky; K Robertson; M Wong; S Musisi; A Ronald; E Katabira
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

7.  Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment.

Authors:  Theresa K Smit; Bruce J Brew; Wallace Tourtellotte; Susan Morgello; Benjamin B Gelman; Nitin K Saksena
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 8.  Preventing HIV antiretroviral resistance through better monitoring of treatment adherence.

Authors:  David R Bangsberg
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

9.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

10.  HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients.

Authors:  J Allen McCutchan; Julia W Wu; Kevin Robertson; Susan L Koletar; Ronald J Ellis; Susan Cohn; Michael Taylor; Steven Woods; Robert Heaton; Judith Currier; Paige L Williams
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

View more
  97 in total

1.  Neuropsychological evaluation and follow up in jcv- and non-jcv-related leukoencephalopathies in HIV infection.

Authors:  C Zucchella; E Sinforiani; E Tavazzi; S Del Bue; S Novati; R Maserati; M Ceroni; S Bastianello; L Minoli; P Ferrante; E Marchioni
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

2.  Independent effects of HIV, aging, and HAART on brain volumetric measures.

Authors:  Beau M Ances; Mario Ortega; Florin Vaida; Jodi Heaps; Robert Paul
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-15       Impact factor: 3.731

3.  Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons.

Authors:  David J Moore; Miguel Arce; Suzanne Moseley; J Allen McCutchan; Jennifer Marquie-Beck; Donald R Franklin; Florin Vaida; Cristian L Achim; Justin McArthur; Susan Morgello; David M Simpson; Benjamin B Gelman; Ann C Collier; Christina M Marra; David B Clifford; Robert K Heaton; Igor Grant
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2011       Impact factor: 2.198

Review 4.  Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport.

Authors:  Italo Mocchetti; Alessia Bachis; Valeriya Avdoshina
Journal:  Neurotox Res       Date:  2011-09-27       Impact factor: 3.911

5.  Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults.

Authors:  Andrew J Levine; Susan Service; Eric N Miller; Sandra M Reynolds; Elyse J Singer; Paul Shapshak; Eileen M Martin; Ned Sacktor; James T Becker; Lisa P Jacobson; Paul Thompson; Nelson Freimer
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-24       Impact factor: 3.568

Review 6.  Neurocognitive impairment and HIV risk factors: a reciprocal relationship.

Authors:  Pria Anand; Sandra A Springer; Michael M Copenhaver; Frederick L Altice
Journal:  AIDS Behav       Date:  2010-12

Review 7.  Neuroimaging with magnetoencephalography: A dynamic view of brain pathophysiology.

Authors:  Tony W Wilson; Elizabeth Heinrichs-Graham; Amy L Proskovec; Timothy J McDermott
Journal:  Transl Res       Date:  2016-01-25       Impact factor: 7.012

8.  Cognitive reserve protects against apathy in individuals with human immunodeficiency virus.

Authors:  Miriam E Shapiro; Jeannette R Mahoney; Deena Peyser; Barry S Zingman; Joe Verghese
Journal:  Arch Clin Neuropsychol       Date:  2013-09-09       Impact factor: 2.813

9.  Pontocerebellar contribution to postural instability and psychomotor slowing in HIV infection without dementia.

Authors:  Edith V Sullivan; Margaret J Rosenbloom; Torsten Rohlfing; Carol A Kemper; Stanley Deresinski; Adolf Pfefferbaum
Journal:  Brain Imaging Behav       Date:  2011-03       Impact factor: 3.978

10.  Apathy correlates with cognitive performance, functional disability, and HIV RNA plasma levels in HIV-positive individuals.

Authors:  Miriam E Shapiro; Jeannette R Mahoney; Barry S Zingman; David L Pogge; Joe Verghese
Journal:  J Clin Exp Neuropsychol       Date:  2013-10-04       Impact factor: 2.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.